3 research outputs found
Recommended from our members
A Study on Hybrid Cars: Environmental Effects and Consumer Habits
The focus of this hybrid vehicle technology paper was whether hybrids meet the expectations for environmental benefits suggested by society. Types of hybrids, the future of the technology, technical aspects of production and efficiency were analyzed and focus groups revealed buyer trends. We concluded that hybrids have drawbacks that offset their fuel efficiency. Their price is generally a poor economic investment and energy efficient processing techniques need to be developed for the advanced materials in hybrids. Widespread change to hybrid technologies is not a feasible option in the near future due to cost and the limited amount of hybrids on the road today. Hybrid technology has potential in the future, but as for right now they are not a significant improvement over today's engine
A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway
Aberrant activation of the classical complement pathway is the common underlying pathophysiology of orphan diseases such as bullous pemphigoid, antibodymediated rejection of organ transplants, cold agglutinin disease, and warm autoimmune hemolytic anemia. Therapeutic options for these complementmediated disorders are limited and sutimlimab, a humanized monoclonal antibody directed against complement factor C1s, may be potentially useful for inhibition of the classical complement pathway. A phase I, firstinhuman, doubleblind, randomized, placebocontrolled, doseescalation trial of single and multiple doses of sutimlimab or placebo was conducted in 64 volunteers to evaluate safety, tolerability, pharmacokinetic, and pharmacodynamic profiles. Single and multiple infusions of sutimlimab were well tolerated without any safety concerns. sutimlimab exhibited a steep concentrationeffect relationship with a Hill coefficient of 2.4, and an IC90 of 15.5 g/mL. This study establishes the foundation for using sutimlimab as a highly selective inhibitor of the classical complement pathway in different diseases.(VLID)340103